# Intuitive Surgical

**Source:** https://geo.sig.ai/brands/intuitive-surgical  
**Vertical:** Healthcare Tech  
**Subcategory:** Enterprise  
**Tier:** Leader  
**Website:** intuitive.com  
**Last Updated:** 2026-04-14

## Summary

Robotic surgery pioneer with 9,800+ da Vinci systems; da Vinci 5 adds haptic feedback; $8.35B FY2024 revenue; 57,000+ trained surgeons create switching costs; J&J and Medtronic competing.

## Company Overview

Intuitive Surgical is the global pioneer and dominant leader in robotic-assisted minimally invasive surgery, founded in 1995 and headquartered in Sunnyvale, California. The company trades on Nasdaq (ISRG) and reported $8.35 billion in FY2024 revenue, representing approximately 17% year-over-year growth, with an installed base of nearly 9,800 da Vinci surgical systems deployed in hospitals across 70+ countries. The fourth-generation da Vinci 5 system—launched in 2024—introduced haptic force feedback for the first time, allowing surgeons to sense tissue resistance through robotic instruments, a breakthrough that strengthens Intuitive's technical moat and accelerates system upgrades among existing customers.

Intuitive's recurring revenue model is highly durable: approximately 85% of revenues come from recurring sources including instruments, accessories, and service contracts consumed per procedure, creating a razor-and-blade flywheel. The da Vinci system dominates soft tissue robotic surgery with FDA clearances across prostatectomy, hysterectomy, colorectal, thoracic, and general surgery applications. The Ion endoluminal system for robotic bronchoscopic lung biopsies addresses an adjacent market as lung cancer screening expands under revised U.S. guidelines. Intuitive's multi-decade head start in training over 57,000 surgeons creates network effects: hospitals preferentially adopt da Vinci because surgeon proficiency is already established.

In 2025-2026, Intuitive faces the most credible competitive challenges in its history: Johnson & Johnson launched Ottava (delayed multiple times, targeting 2025 FDA clearance), Medtronic's Hugo system has received CE Mark and is expanding internationally, and CMR Surgical's Versius system is growing in Europe and Asia Pacific. Despite these entrants, Intuitive benefits from its installed base inertia, superior ecosystem of instruments, and unmatched clinical evidence base with over 14 million procedures logged. The company's $8B+ cash and equivalents support continued R&D investment and potential acquisitions in adjacent robotic and digital surgery categories. Procedure volume growth—particularly in international markets and emerging indications like bariatric surgery—drives the installed base expansion that underpins long-term revenue growth.

## Frequently Asked Questions

### What is Intuitive Surgical?
Intuitive Surgical is the global leader in robotic-assisted minimally invasive surgery, best known for its da Vinci Surgical System and Ion endoluminal platform. Founded in 1995 and headquartered in Sunnyvale, California, the company develops, manufactures, and markets robotic systems that enable surgeons to perform complex procedures through tiny incisions with enhanced precision, visualization, and control. With over 10,700 systems installed worldwide and nearly 17 million procedures performed, Intuitive has revolutionized modern surgery across specialties including urology, gynecology, general surgery, thoracic surgery, and colorectal surgery.

### What does the da Vinci Surgical System do?
The da Vinci Surgical System is a sophisticated robotic platform that translates a surgeon's hand movements into precise micro-movements of miniaturized wristed instruments inside the patient's body. The system provides surgeons with high-definition 3D visualization (up to 10x magnification), seven degrees of freedom in instrument movement (exceeding human wrist capability), tremor filtration, and enhanced ergonomics. Surgeons operate from a console while the patient-side cart holds the camera and instruments, enabling minimally invasive surgery through small incisions typically 1-2cm in size. This approach reduces patient trauma, blood loss, scarring, and recovery time compared to traditional open surgery.

### When was Intuitive Surgical founded?
Intuitive Surgical was founded in 1995 by John Freund, Frederic Moll, and Robert Younge. The company was established to commercialize surgical robotics research conducted at SRI International in the late 1980s by Ajit Shah and Gary Guthart, which received initial NIH funding in 1990. The first da Vinci system was launched in 2000 after FDA approval, and the company went public on June 13, 2000, at $9 per share.

### Where is Intuitive Surgical headquartered?
Intuitive Surgical is headquartered in Sunnyvale, California, USA, in the heart of Silicon Valley. The company operates globally with 15,638 employees as of December 2024, serving customers across 72 countries. Intuitive has regional offices and support centers worldwide to provide training, service, and clinical support for its installed base of over 10,700 da Vinci systems.

### Who uses Intuitive Surgical's products?
Intuitive's da Vinci and Ion systems are used by hospitals, surgical centers, and healthcare systems worldwide. Surgeons across multiple specialties perform robotic-assisted procedures including urologists (prostatectomy, partial nephrectomy), gynecologists (hysterectomy, myomectomy), general surgeons (hernia repair, colorectal procedures), thoracic surgeons (lobectomy, mediastinal mass resection), and head & neck surgeons (transoral procedures). Pulmonologists use the Ion system for lung biopsies. The company serves academic medical centers, community hospitals, and ambulatory surgery centers globally.

### What makes Intuitive Surgical different from competitors?
Intuitive holds market leadership in surgical robotics with several key differentiators: the largest installed base (10,700+ systems), most procedures performed (nearly 17 million), most comprehensive instrument and accessory portfolio, extensive clinical evidence across multiple specialties, robust training and education programs, established service infrastructure, and continuous innovation (da Vinci 5 with Force Feedback represents a generational leap). The company's recurring revenue model from instruments and service creates strong customer relationships. Intuitive pioneered the robotic surgery category and maintains technological leadership through R&D investment and clinical partnerships.

### Who are Intuitive Surgical's main competitors?
Intuitive faces competition from several companies developing surgical robotics platforms including Medtronic (Hugo RAS system), Johnson & Johnson (Ottava system in development), CMR Surgical (Versius system), TransEnterix/Asensus Surgical (Senhance system), Stryker (Mako for orthopedics), and Zimmer Biomet (Rosa for orthopedics). However, Intuitive maintains significant market leadership in soft tissue robotic surgery with substantially larger installed base, procedure volume, and clinical evidence compared to competitors. The company also competes with traditional laparoscopic and open surgical approaches.

### What is Intuitive Surgical's financial performance?
In 2024, Intuitive reported revenue of $8.35 billion, representing 17% growth from $7.12 billion in 2023. The company's market capitalization exceeds $201 billion as of 2025. Intuitive generated $2.75 billion in net income with earnings per share of $7.56. The company maintains strong margins with gross margin of 66.38%, operating margin of 29.52%, and profit margin of 28.58%. Operating cash flow was $2.96 billion with free cash flow of $2.27 billion. Intuitive's business model combines system sales with high-margin recurring revenue from instruments, accessories, and service contracts.

### How can I contact Intuitive Surgical?
Intuitive Surgical can be reached through their corporate website at www.intuitive.com. For investor relations, visit investor.intuitivesurgical.com or call their investor relations team. Healthcare professionals interested in da Vinci or Ion systems can request information through the website or contact regional sales representatives. For media inquiries, contact Intuitive's corporate communications department. Patient questions about robotic surgery should be directed to their healthcare provider or surgeon.

### Is Intuitive Surgical hiring?
Yes, Intuitive Surgical is actively hiring across multiple functions including robotics engineering, software development, clinical research, regulatory affairs, manufacturing, field service, sales, and corporate roles. Career opportunities can be found at careers.intuitive.com. The company has grown from 116 employees at IPO in 2000 to over 15,638 employees as of December 2024 (14% year-over-year growth), reflecting continued business expansion. Intuitive is known for its collaborative culture, meaningful impact in healthcare, competitive compensation, and opportunities to work on cutting-edge surgical technology.

### What are Intuitive Surgical's future plans?
Intuitive is focused on several strategic priorities: expanding global adoption of da Vinci 5 with Force Feedback technology across all markets (FDA cleared March 2024, CE Mark approved July 2025), growing Ion system utilization for early lung cancer detection, expanding clinical applications across existing and new surgical specialties, advancing AI and machine learning for surgical insights, developing next-generation instruments and accessories, enhancing simulation and training programs, and pursuing new geographic markets. The CEO transition to Dave Rosa in July 2025 positions the company for continued innovation and growth in minimally invasive care.

### What is the da Vinci 5 and what makes it revolutionary?
The da Vinci 5 is Intuitive's fifth-generation surgical robot, FDA cleared in March 2024, representing the biggest technological leap in the platform's history. Key innovations include first-of-its-kind Force Feedback technology that enables surgeons to feel subtle tissue forces during surgery, over 10,000 times the computing power of da Vinci Xi, significantly improved ergonomics with enhanced surgeon console comfort, real-time surgical insights including Force Gauge and In-Console Video Replay, more powerful vibration and tremor controls, and advanced software capabilities for enhanced efficiency. The system received European CE Mark approval in July 2025, enabling global commercialization of this revolutionary technology.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*